secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENANTA PHARMACEUTICALS INC (ENTA)
CIK:        0001177648
Form:       8-K
Filed at:   2025-09-29T23:59:59+00:00
Accession:  0001193125-25-221791
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enanta reports positive Phase 2b topline data for zelicapavir in high-risk RSV adults
--------------------------------------------------------------------------------

- Phase 2b study of zelicapavir (formerly EDP-938) met primary endpoint in high-risk adults with RSV.
- Topline results announced September 29, 2025; detailed data presented in slide presentation.
- Zelicapavir is an oral antiviral; no specific efficacy or safety numbers disclosed in the 8-K.
- Positive outcome supports advancement; further details expected in future medical meetings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1177648/000119312525221791/0001193125-25-221791-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1177648/000119312525221791/d65423d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-221791

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer